Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR- agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Disclaimer: Reposts and posts of contents are for informational purposes only and do not constitute endorsements or promotions of any third-party products, services or organizations (including any statements, views or conducts by such organizations) unless explicitly stated otherwise

Pharmaceuticals,liver disease,life sciences,and biopharmaceuticals

Terns pharmaceuticals operates in the Biotechnology research industry.

Terns pharmaceuticals's revenue is 11m - 100m

Terns pharmaceuticals has 51 - 200 employees.